Abstract
The study aims to evaluate the costs and outcomes associated with first-line daratumumab use plus lenalidomide (DRd) for transplant-ineligible multiple myeloma patients, compared to reserving its use for second line following treatment with a bortezomib-based regimen (VRd) from the Singapore health system perspective.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
